Protective Role of Methylene Blue in Alzheimer's Disease via Mitochondria and Cytochrome c Oxidase
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
The key cytopathologies in the brains of Alzheimer's disease (AD) patients include mitochondrial dysfunction and energy hypometabolism, which are likely caused by the accumulation of toxic species of amyloid-beta (Abeta) peptides. This review discusses two potential approaches to delay the onset of AD. The first approach is use of diaminophenothiazines (e.g., methylene blue; MB) to prevent mitochondrial dysfunction and to attenuate energy hypometabolism. We have shown that MB increases heme synthesis, cytochrome c oxidase (complex IV), and mitochondrial respiration, which are impaired in AD brains. Consistently, MB is one of the most effective agents to delay senescence in normal human cells. A key action of MB appears to be enhancing mitochondrial function, which is achieved at nM concentrations. We propose that the cycling of MB between the reduced leucomethylene blue (MBH2) and the oxidized (MB) forms may explain, in part, the mitochondria-protecting activities of MB. The second approach is use of naturally occurring osmolytes to prevent the formation of toxic forms of Abeta. Osmolytes (e.g., taurine, carnosine) are brain metabolites typically accumulated in tissues at relatively high concentrations following stress conditions. Osmolytes enhance thermodynamic stability of proteins by stabilizing natively-folded protein conformation, thus preventing aggregation, without perturbing other cellular processes. Experimental evidence suggests that the level of carnosine is significantly lower in AD patients. Osmolytes may inhibit the formation of Abeta species in vivo, thus preventing the formation of soluble oligomers. Osmolytes are efficient antioxidants that may also increase neural resistance to Abeta. The potential significance of combining MB and osmolytes to treat AD are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · cited 1×
“The most accepted view for the pathological mechanism of AD is the accumulation of small peptides known as amyloid-β (Aβ) in the brains of AD patients [1].”
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · cited 1×
“This hypothesis emerged from experiments showing that Aβ oligomers inhibit long-term potentiation (LTP), a classic experimental paradigm for memory and synaptic plasticity [24,25].”
Copper, iron and zinc in Alzheimer's disease senile plaques
Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., & Markesbery, W. R. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00092-6 · Cited by 2,120
Yancey, P. H. (2005) · Journal of Experimental Biology · doi:10.1242/jeb.01730 · Cited by 1,868
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856 · cited 1×
“Several lines of research show that an increase in soluble dimeric and oligomeric forms of Aβ, which precede the appearance of senile plaques [13–15], correlate with early cognitive impairment in AD [16,17].”
Mitochondrial abnormalities in Alzheimer's disease
Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R. L., Atwood, C. S., Johnson, A. B., Kress, Y., Vinters, H. V., Tabaton, M., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-09-03017.2001 · Cited by 1,367 · cited 1×
“The brain is particularly sensitive to mitochondrial dysfunction, the resulting oxidative stress, and impaired energy metabolism [64–66].”
ABAD Directly Links Aß to Mitochondrial Toxicity in Alzheimer's Disease
Lustbader, J. W., Cirilli, M., Lin, C., Xu, H. W., Takuma, K., Wang, N., Caspersen, C., Chen, X., Pollak, S., Chaney, M., et al. (2004) · Science · doi:10.1126/science.1091230 · Cited by 1,303
Intranasal delivery to the central nervous system: Mechanisms and experimental considerations
Dhuria, S. V., Hanson, L. R., & Frey, W. H. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21924 · Cited by 1,239 · cited 2×
“to the brain [68] may prove valuable for AD patients.”
Manczak, M., Anekonda, T. S., Henson, E., Park, B. S., Quinn, J., & Reddy, P. H. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl066 · Cited by 1,104
Cited by
Smith, R. A. J., Hartley, R. C., Cochemé, H. M., & Murphy, M. P. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.03.010 · Cited by 499
“Lest we forget you — methylene blue …”
Schirmer, R. H., Adler, H., Pickhardt, M., & Mandelkow, E. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.12.012 · Cited by 414
Corona, C., Frazzini, V., Silvestri, E., Lattanzio, R., La Sorda, R., Piantelli, M., Canzoniero, L. M. T., Ciavardelli, D., Rizzarelli, E., & Sensi, S. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017971 · Cited by 182
“acting as an osmolyte as shown in the case of its action on methylene blue and cytochrome c oxidase [42].”
BackgroundAnti-Aging Potentials of Methylene Blue for Human Skin Longevity
Xiong, Z.-M., O’Donovan, M., Sun, L., Choi, J. Y., Ren, M., & Cao, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-02419-3 · Cited by 112
The association between PGC-1α and Alzheimer's disease
Sweeney, G., & Song, J. (2016) · Anatomy & Cell Biology · doi:10.5115/acb.2016.49.1.1 · Cited by 93
“Impaired mitochondrial function leads to a severe loss in energy metabolism and ATP generation [47], and also to a deficiency in the scavenging of free radicals which triggers excessive oxidative damage in the AD brain [48, 49].”
BackgroundMitochondrial Abnormalities in Alzheimer’s Disease
Silva, D. F., Selfridge, J. E., Lu, J., E, L., Cardoso, S. M., & Swerdlow, R. H. (2012) · Advances in Pharmacology · doi:10.1016/b978-0-12-394816-8.00003-9 · Cited by 86
Lee, K. K., & Boelsterli, U. A. (2014) · Redox Biology · doi:10.1016/j.redox.2014.03.003 · Cited by 57
Zakaria, A., Hamdi, N., & Abdel-Kader, R. M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-014-9088-8 · Cited by 53
Oxidative Status Predicts Quality in Human Mesenchymal Stem Cells
Bertolo, A., Capossela, S., Fränkl, G., Baur, M., Pötzel, T., & Stoyanov, J. (2017) · Stem Cell Research & Therapy · doi:10.1186/s13287-016-0452-7 · Cited by 36
“It acts as a substitute electron carrier that can bypass the compromised electron transport chain at proximal complexes, interacting with complex I and cytochrome c [24].”
BackgroundMethylene Blue Protects Primary Rat Retinal Ganglion Cells from Cellular Senescence
Daudt, D. R., Mueller, B., Park, Y. H., Wen, Y., & Yorio, T. (2012) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-9734 · Cited by 35
H. Swerdlow, R. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211798072535 · Cited by 35
A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer’s Disease
Ettcheto, M., Busquets, O., Espinosa-Jiménez, T., Verdaguer, E., Auladell, C., & Camins, A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200211121416 · Cited by 13
Metadata
- Authors
- Atamna, H., & Kumar, R.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2010-06-03
- Volume
- 20
- Issue
- s2
- Pages
- S439-S452
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1479794699
- Cited by
- 136
- References
- 33
- FWCI
- 6.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.